SecBot SecBot

ABEO drug pipeline

ABEONA THERAPEUTICS INC. · 3 rated drugs
$2.60
+7.4% 1-day · Nov 16
Next catalyst
None dated
No dated FDA catalyst on file
Typical move on FDA news
No history
No past FDA events with prices
IV rank
No data
No current options data
Rated drugs
3
3 neutral
Phase 3 trials
0
0 with results posted

Drugs

soonest catalyst first
● neutral
Impact
PhasePhase 2 completed / Phase 3-ready
Time to marketABO-801 is Phase 3-ready but no Phase 3 trial has been announced. Assuming a typical 1-2 year Phase 3 program plus FDA review, potential approval would be at least 3-4 years away, though the Fast Track designation could accelerate the timeline.

ABO-801 Updated Nov 9

What to watch

Watch for the initiation of a Phase 3 trial for ABO-801 in eosinophilic esophagitis, which would be the next meaningful drug-specific catalyst. Near term, monitor the activist investor situation (James Russell's 6.1% stake and board-change demands) and the registration statement filing for the PIPE shares, as these could drive further volatility. The Q3 earnings beat and ZEVASKYN revenue growth ($13.5M, up 18% QoQ) provide a commercial foundation, but the dilutive financing and activist pressure create a mixed setup.

Bull case
  • Pipeline diversification: ABO-801 adds a Phase 3-ready, non-gene-therapy asset to Abeona's pipeline, reducing single-asset dependence on ZEVASKYN.
  • Favorable deal structure: Abeona acquired ABO-801 for $20M in stock with no upfront cash, plus up to $60M in milestones and tiered royalties, limiting downside if the drug fails.
  • FDA designations: ABO-801 has both FDA Orphan Drug and Fast Track designations for eosinophilic esophagitis, which can accelerate development and provide market exclusivity.
Bear case
  • Significant dilution: the $30M PIPE at $3.75/share and $20M stock consideration for the acquisition dilute existing holders by roughly 13-25%, and the stock was down ~16% in pre-market trading on the announcement day.
  • Activist pressure: James Russell disclosed a 6.1% stake on October 23, 2026 and is pushing for board and leadership changes, adding governance uncertainty.
  • Insider selling: Four senior executives (CEO, CFO, CLO, CCO) sold shares on September 29, 2026 at ~$5.16, and a director sold on September 1, 2026 at ~$5.86.
● neutral
Impact
PhaseApproved
Time to marketAlready approved and commercially launched in the U.S. (April 2025).

ZEVASKYN prademagene zamikeracel Updated Sep 12

What to watch

ZEVASKYN is already approved and generating revenue, so the binary approval catalyst is behind it. Watch quarterly commercial metrics (patient starts, revenue growth, treatment center expansion) and the CMS NTAP designation effective October 2026 for reimbursement tailwinds. The stock's ~214% implied upside to the mean analyst target reflects optimism on commercial ramp, but ongoing cash burn and EPS misses warrant caution.

Bull case
  • First and only FDA-approved treatment for RDEB, a severe rare disease with no prior approved therapies, strong orphan drug positioning
  • Commercial revenue growing rapidly: $2.4M in Q4 2025 → $8.7M in Q1 2026 → $11.4M in Q2 2026 (31% QoQ growth)
  • Analyst consensus strongly bullish: 11 of 12 analysts rate Buy/Strong Buy, mean price target $18.86 (~214% upside from ~$5.42)
Bear case
  • Company is unprofitable with widening net losses: -$17.1M in Q1 2026 and -$20.2M in Q2 2026, with EPS misses
  • ZEVASKYN is an autologous cell therapy requiring a complex, individualized manufacturing process, scalability and capacity constraints could limit revenue growth
  • As a surgically grafted cell-sheet therapy, patient access is limited to specialized treatment centers (only 5 activated so far)
● neutral
Impact
PhasePreclinical
Time to marketUnknown — at least 4-6 years away if clinical trials succeed. IND filing is expected H2 2027, followed by Phase 1/2 trials that typically take 2-3 years, then pivotal trials.

ABO-701 PSMA-SIR-T Updated Sep 12

What to watch

ABO-701 is too early-stage (preclinical, IND expected H2 2027) to drive ABEO's share price in the next 12 months. Investors should focus on ZEVASKYN commercial execution (patient treatment volumes, revenue growth, manufacturing yields) as the primary near-term value driver. Any ABO-701-related moves would be speculative and tied to broader pipeline sentiment rather than a hard catalyst.

Bull case
  • PSMA is a well-validated target in prostate cancer, and a gene therapy approach could offer a novel treatment option if clinical data support it.
  • Abeona has gene therapy expertise from ZEVASKYN (already approved), which could accelerate ABO-701 development.
  • Analyst consensus is strongly bullish on ABEO (11 Buy/Strong Buy vs 1 Hold), with a mean price target of $18.86 implying ~214% upside from ~$5.42.
Bear case
  • ABO-701 is preclinical, no clinical data exist yet. Most preclinical candidates never make it to approval.
  • IND filing is not expected until H2 2027, meaning no near-term catalyst for at least 12+ months.
  • Abeona's cash burn ($44.6M in H1 2026) and $146.8M remaining cash may require additional financing before ABO-701 reaches the clinic.